2016 Innovation Grants - Professor Des Richardson
New therapeutic tools
Drug resistance is a major factor underlying the limited response of pancreatic cancer to chemotherapy. The project team’s drug design strategy is to target resistant pancreatic cancer by taking advantage of detoxifying P-glycoprotein pump to transport our drugs DIRECTLY to their sensitive site of action in the cancer cell (namely, the LYSOSOME).

Professor Des Richardson